Murie N, Rio M, Scarabin J M, Auvray E
Nouv Presse Med. 1978 Jun 10;7(23):2035-40.
Seventy tests of stimulation with hypothalamic thyreotrophic hormone liberation factor, and 35 bromocriptine inhibition tests were carried out on a routine basis in patients with latent or frank hyperprolactinaemia. Pathological hyperprolactinaemia does not have a single clinical pattern: frank, it takes the form either of an exteriorised pituitary adenoma (14 cases), or of an amenorrhoea-galactorrhoea syndrome with or without micro-adenoma (12 cases); latent, it takes the form either of isolated amenorrhoea (17 cases) or of dysovulatory sterility (16 cases). Amongst the dynamic tests available, it is worthwhile to make a choice, and in the case of frank hyperprolactinaemia, the authors propose use of the bromocriptine inhibition test in the first instance. The TRH test is reserved for verification of the results of neurosurgery. As far as latent hyperprolactinaemia is concerned, it may be identify only by the TRH test, with the resultant possibility of specific treatment.
对患有潜在或明显高泌乳素血症的患者，常规进行了70次下丘脑促甲状腺激素释放因子刺激试验和35次溴隐亭抑制试验。病理性高泌乳素血症没有单一的临床模式：明显的高泌乳素血症，其表现形式要么是垂体腺瘤外露（14例），要么是伴有或不伴有微腺瘤的闭经-溢乳综合征（12例）；潜在的高泌乳素血症，其表现形式要么是单纯闭经（17例），要么是排卵障碍性不孕（16例）。在现有的动态试验中，有必要进行选择，对于明显的高泌乳素血症，作者建议首先使用溴隐亭抑制试验。促甲状腺激素释放激素（TRH）试验则留作神经外科手术结果的验证。就潜在性高泌乳素血症而言，可能只能通过TRH试验来识别，从而有可能进行特异性治疗。
